Hongnan Mo

2.4k total citations · 2 hit papers
54 papers, 1.5k citations indexed

About

Hongnan Mo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Hongnan Mo has authored 54 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Hongnan Mo's work include Cancer Immunotherapy and Biomarkers (13 papers), HER2/EGFR in Cancer Research (12 papers) and Advanced Breast Cancer Therapies (12 papers). Hongnan Mo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), HER2/EGFR in Cancer Research (12 papers) and Advanced Breast Cancer Therapies (12 papers). Hongnan Mo collaborates with scholars based in China, United States and Hong Kong. Hongnan Mo's co-authors include Peng Liu, Binghe Xu, Fei Ma, Jing Huang, Dawei Wu, Xiaoying Sun, Bo Lan, Xuelian Chen, Dong Qu and Hongyan Chen and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hongnan Mo

49 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

2021 434 citations Yuanyuan Zhang, Hongyan Chen et al. Cancer Cell profile →
Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer

2025 25 citations Yuanyuan Zhang, Hongyan Chen et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hongnan Mo China	17	1.0k	427	381	372	341	54	1.5k
Débora De Melo Gagliato Brazil	14	953 0.9×	528 1.2×	281 0.7×	426 1.1×	501 1.5×	36	1.5k
Autumn J. McRee United States	15	1.1k 1.1×	579 1.4×	313 0.8×	300 0.8×	180 0.5×	51	1.5k
Luisa Carbognin Italy	20	928 0.9×	402 0.9×	259 0.7×	337 0.9×	320 0.9×	67	1.3k
Leila Khoja United Kingdom	20	1.7k 1.7×	612 1.4×	403 1.1×	416 1.1×	388 1.1×	50	2.1k
Carmen Belli Italy	20	1.0k 1.0×	517 1.2×	248 0.7×	550 1.5×	401 1.2×	60	1.7k
Juan Martín-Liberal Spain	19	1.1k 1.1×	431 1.0×	415 1.1×	346 0.9×	163 0.5×	84	1.6k
Louise C. Connell United States	8	1.2k 1.2×	347 0.8×	376 1.0×	242 0.7×	107 0.3×	31	1.6k
Arantza Fariña Sarasqueta Netherlands	22	1.0k 1.0×	366 0.9×	227 0.6×	437 1.2×	284 0.8×	83	1.8k
Young Wha Koh South Korea	26	892 0.9×	563 1.3×	319 0.8×	407 1.1×	242 0.7×	82	1.7k
Giovanni Fucà Italy	23	1.2k 1.1×	549 1.3×	293 0.8×	382 1.0×	204 0.6×	87	1.8k

Countries citing papers authored by Hongnan Mo

Since Specialization

Citations

This map shows the geographic impact of Hongnan Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongnan Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongnan Mo more than expected).

Fields of papers citing papers by Hongnan Mo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongnan Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongnan Mo. The network helps show where Hongnan Mo may publish in the future.

Co-authorship network of co-authors of Hongnan Mo

This figure shows the co-authorship network connecting the top 25 collaborators of Hongnan Mo. A scholar is included among the top collaborators of Hongnan Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongnan Mo. Hongnan Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lan, Bo, Jiayu Wang, Qiao Li, et al.. (2025). The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study. The Breast. 81. 104470–104470. 3 indexed citations

Ma, Fei, Ting Wang, Dongkui Xu, et al.. (2025). STS2 deficiency revives CD8⁺T cells from exhaustion and augments checkpoint blockade efficacy in cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 13(6). e010735–e010735. 1 indexed citations

Zhang, Yuanyuan, Hongyan Chen, Hongnan Mo, et al.. (2025). Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. Cancer Cell. 43(3). 446–463.e7. 25 indexed citations breakdown →

Mo, Hongnan, Yongpei Yu, Xiaoying Sun, et al.. (2024). Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nature Medicine. 30(9). 2528–2539. 11 indexed citations

Jiang, Mingxia, Mengqi Zhang, Yiqun Li, et al.. (2024). Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study. BMC Cancer. 24(1). 1290–1290. 1 indexed citations

Wang, Ting, Chunxiao Li, Nan Peng, et al.. (2023). MTA1, a Novel ATP Synthase Complex Modulator, Enhances Colon Cancer Liver Metastasis by Driving Mitochondrial Metabolism Reprogramming. Advanced Science. 10(25). e2300756–e2300756. 27 indexed citations

Mo, Hongnan, Xuefeng Liu, Hongyan Chen, et al.. (2022). S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer. Molecular Cancer. 21(1). 171–171. 26 indexed citations

Zhai, Jingtong, Xiaoying Sun, Fang Zhao, et al.. (2022). Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study. The Breast. 67. 36–45. 4 indexed citations

Zhang, Yuanyuan, Hongyan Chen, Hongnan Mo, et al.. (2021). Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 39(12). 1578–1593.e8. 434 indexed citations breakdown →

10.

Yi, Zongbi, Fei Ma, Guohua Rong, et al.. (2021). The molecular tumor burden index as a response evaluation criterion in breast cancer. Signal Transduction and Targeted Therapy. 6(1). 251–251. 31 indexed citations

11.

Wang, Jiayu, Fei Ma, Yang Luo, et al.. (2020). Platinum‐based chemotherapy in advanced triple‐negative breast cancer: A multicenter real‐world study in China. International Journal of Cancer. 147(12). 3490–3499. 9 indexed citations

12.

Mo, Hongnan, Xiaobing Wang, Fei Ma, et al.. (2020). Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer. The Breast. 53. 111–118. 10 indexed citations

13.

Mo, Hongnan, Yiqun Li, Xiuwen Guan, et al.. (2020). Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China. The Breast. 53. 172–180. 14 indexed citations

14.

Jiang, Shiyu, Sheng Yang, Jianliang Yang, et al.. (2019). Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China. BMJ Open. 9(5). e028589–e028589. 1 indexed citations

15.

Chen, Xuelian, Hongnan Mo, Dawei Wu, et al.. (2019). Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210. Cancer Biology and Medicine. 16(1). 173–173. 46 indexed citations

16.

Zhang, Bo, Xi Wang, Qun Li, et al.. (2019). Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma. Chinese Journal of Cancer Research. 31(6). 910–917. 13 indexed citations

17.

Huang, Jing, Binghe Xu, Hongnan Mo, et al.. (2018). Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. Clinical Cancer Research. 24(6). 1296–1304. 149 indexed citations

18.

Hu, Xingsheng, Xixi Zheng, Hongnan Mo, et al.. (2018). P1.01-37 BPI-9016M, a Novel c-Met Inhibitor, in Pretreated Advanced Solid Tumor: Results from a First-In-Human, Phase 1, Dose-Escalation Study. Journal of Thoracic Oncology. 13(10). S474–S474. 1 indexed citations

19.

Mo, Hongnan, Xuezhi Hao, Yutao Liu, et al.. (2016). A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients. Cancer Medicine. 5(6). 1116–1124. 5 indexed citations

20.

Mo, Hongnan, et al.. (2000). Screening of hollow organ tumours by occult blood test. European Journal of Cancer Prevention. 9(5). 367–370. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact